• Surgical oncology · Mar 2019

    HIPEC and CRS in peritoneal metastatic gastric cancer - who really benefits?

    • Thomas Hotopp.
    • Medizinisches Versorgungszentrum des Deutschen Roten Kreuzes, An der Wipper 2, 06567, Bad Frankenhausen, Germany. Electronic address: thomas.hotopp@kliniken-drk.de.
    • Surg Oncol. 2019 Mar 1; 28: 159-166.

    BackgroundGastric cancer with the presence of peritoneal metastases (pmgc) is associated with a very poor prognosis. Despite the wide utilization and promising results of the multimodal treatment regimens including cytoreductive surgery (CRS) and a subsequent hyperthermic intraperitoneal chemotherapy (HIPEC), it is still not fully understood which patient group is suitable for this treatment.MethodsTwenty-six patients (median age 53 years, range 39-71) were scheduled for three cycles of neoadjuvant systemic chemotherapy using bi-weekly FLOT-protocol followed by CRS + HIPEC. After this treatment 3 additional cycles of FLOT were given. During HIPEC Oxaliplatin was applied in a dosage of 200 mg/m2 and Docetaxel in a dosage of 80 mg/m2.ResultsAll patients underwent the standardized multimodal treatment including FLOT, CRS and HIPEC. This treatment resulted in an overall survival (OS) of 17 months in comparison to 6 months as the outcome of the classic treatments. Regression analysis demonstrated a Peritoneal Cancer Index (PCI) ≥ 12 as a negative factor for survival. Furthermore, we could see a worse prognosis by a higher temperature (>41,4 °C) of the chemotherapy used for the HIPEC. In consideration of the gender, the histomorphology and the Laurén-classification, we could develop a precise score to define the patient group which will benefit from this multimodal treatment with a prognosis improvement of 24 months.ConclusionNeoadjuvant chemotherapy using the FLOT-protocol followed by CRS + HIPEC seems to be associated with prolonged OS in patients with peritoneal carcinomatosis from gastric cancer. This treatment needs a critical evaluation for patients with a PCI ≥12. Furthermore, the accurate selection of patients suffering of PMGC by using the developed score can improve the OS of up to 24 months for a suitable group and it can avoid the extensive treatment for unsuitable patients.Copyright © 2019 Elsevier Ltd. All rights reserved.

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…

Want more great medical articles?

Keep up to date with a free trial of metajournal, personalized for your practice.
1,704,841 articles already indexed!

We guarantee your privacy. Your email address will not be shared.